Introduction
Medication non-adherence is a significant barrier to effective chronic disease management, impacting patient outcomes and healthcare costs. Consequently, reliable tools to assess adherence are critical for clinicians and researchers. The Morisky Medication Adherence Scale-8 (MMAS-8), developed by Donald E. Morisky in 2008, and published by MMAR, LLC dba ADHERENCE, is a widely used, validated instrument for evaluating medication adherence in patients with chronic conditions such as hypertension and diabetes. With over 4,000 citations on Google Scholar, the MMAS-8 has established itself as a cornerstone in health behavior research (Morisky et al., 2008).
This article provides a comprehensive guide for experts, detailing the MMAS-8’s features, applications, and value in clinical and research settings.
Key Features of the Morisky Medication Adherence Scale-8 (MMAS-8)
Purpose and Use
The MMAS-8 assesses medication adherence in patients with chronic conditions, focusing on both intentional and unintentional non-adherence. Specifically, it helps clinicians identify barriers to adherence and supports researchers in studying treatment effectiveness. Moreover, its concise design makes it ideal for busy clinical environments and large-scale studies.
Target Population
The MMAS-8 targets adults aged 18 and older, including young adults (18–24), middle-aged adults (25–44), older adults (45–64), and seniors (65+). Specifically, it is designed for patients with chronic diseases such as hypertension, diabetes, and asthma, making it highly relevant for chronic care settings.
Structure
The MMAS-8 comprises 8 questions covering various aspects of medication adherence:
- Item 1: Forgetfulness (unintentional non-adherence)
- Item 2: Recent unintentional non-adherence (not due to forgetfulness)
- Item 3: Intentional non-adherence when feeling worse
- Item 4: Travel-related forgetfulness
- Item 5: Recent adherence (reverse-coded)
- Item 6: Intentional non-adherence when feeling better
- Item 7: Burden of medication regimens
- Item 8: Frequency of forgetfulness
Items 1–7 use yes/no responses, while Item 8 employs a 5-point Likert scale (never to always), ensuring a nuanced assessment of adherence behaviors.
Administration Format
The MMAS-8Â takes less than 5 minutes to administer, making it highly efficient. It can be conducted via:
- Paper-based forms
- Digital (Online) platforms
- In-person (Interview)
- Phone/Video call
Its self-administered format, requiring no specialized training, enhances its practicality for busy clinical environments.
Applications of Morisky Medication Adherence Scale-8 (MMAS-8)
The MMAS-8 offers significant value in clinical and research settings:
- Screening: Identifies patients with low adherence to medications.
- Diagnosis: Supports assessment of adherence-related issues in chronic disease management.
- Monitoring: Tracks adherence over time, particularly during treatment adjustments.
- Treatment Planning: Informs strategies to improve patient adherence.
- Research: Widely used in studies evaluating interventions for chronic disease management.
For example, clinicians can use the MMAS-8 to identify barriers to adherence in diabetic patients, while researchers can assess the impact of adherence on clinical outcomes
Languages and Availability
To support global use, the MMAS-8 is available in over 30 languages, including:
- Arabic
- English
- Mandarin Chinese
- Spanish
- French
- Russian
- German
- Portuguese
- Japanese
- Hindi
- As well as more than 30 languages.
This extensive multilingual availability enhances its applicability in diverse clinical and research context.
The MMAS-8 is a copyrighted instrument under a proprietary license. Permission from MMAR, LLC dba Adherence is required for its use in clinical or research settings. Researchers and clinicians must contact MMAR, LLC to obtain a license, ensuring compliance with copyright laws.
Reliability and Validity
The MMAS-8 is recognized as a highly reliable and valid instrument for assessing medication adherence. Its psychometric strength is demonstrated by a Cronbach’s alpha of 0.83, indicating good internal consistency. Additionally, it shows strong test-retest reliability, ensuring stability over time.
Validation Study:
Limitations and Considerations
However, despite its strengths, the MMAS-8 has a few limitations:
- Self-report: Patients may underreport non-adherence due to social desirability bias.
- Cultural Bias: May require adaptations for optimal use in certain cultural contexts.
- Narrow Focus: Focuses solely on medication adherence, missing broader health behavior factors.
- Age Restrictions: Not suitable for patients under 18, requiring alternative tools for younger populations.
These limitations suggest that clinicians and researchers should complement the MMAS-8 with objective adherence measures or culturally tailored tools when necessary.
Other Versions and Related Questionnaires
Alternative Versions of MMAS-8
- MMAS-4: A shorter, 4-item version for rapid adherence screening in time-constrained settings.
Complementary Questionnaires
- Medication Adherence Report Scale (MARS): Assesses adherence behaviors with a focus on patient-reported outcomes.
- Brief Medication Questionnaire (BMQ): Evaluates adherence and barriers in a concise format.
Additional Resources
For more information on the MMAS-8 and to access the full questionnaire, visit the following resources:
- Download the MMAS-8 Questionnaire (PDF)
- Official Source
- For inquiries, contact MMAR, LLC dba Adherence.
- For additional MMAS-8 resources, consult www.moriskyscale.com.
Frequently Asked Questions (FAQ)
- Who can use the MMAS-8?
Clinicians and researchers use the MMAS-8 for adults aged 18+ with chronic conditions like hypertension or diabetes. - How long does it take to complete the MMAS-8?
Patients typically take less than 5 minutes to complete the MMAS-8, making it efficient for clinical use. - How is the MMAS-8 administered?
The MMAS-8 can be administered via paper-based, digital (online), in-person interview, or phone/video call formats, offering flexibility. - Is there any cost to using the MMAS-8?
The MMAS-8 requires permission from MMAR, LLC for use, as it is a copyrighted instrument.
A word from ResRef about Morisky Medication Adherence Scale-8 (MMAS-8)
The Morisky Medication Adherence Scale-8 (MMAS-8) is a validated, self-report questionnaire designed to assess medication adherence in patients with chronic conditions. The MMAS-8 has demonstrated acceptable internal consistency and reliability across various chronic conditions, including hypertension, diabetes, and asthma. Its validity has been confirmed in multiple languages and cultural contexts, making it a versatile tool for both clinical practice and research. It’s important to note that the MMAS-8 is a copyrighted instrument, and proper licensing is required for its use in clinical or research settings.
References
- Morisky, D. E., Ang, A., Krousel-Wood, M., & Ward, H. J. (2008). Predictive validity of a medication adherence measure in an outpatient setting. The Journal of Clinical Hypertension, 10(5), 348–354. (link)
- Martinez-Perez, P., Orozco-Beltrán, D., Pomares-Gomez, F., Hernández-Rizo, J. L., Borras-Gallen, A., Gil-Guillen, V. F., Quesada, J. A., Lopez-Pineda, A., & Carratala-Munuera, C. (2021). Validation and psychometric properties of the 8-item Morisky Medication Adherence Scale (MMAS-8) in type 2 diabetes patients in Spain. Atención Primaria, 53(2), 101942. (link)
4 thoughts on “Morisky Medication Adherence Scale-8 (MMAS-8): A Full Guide for Researchers and Clinicians”
I would like to use the MMAS-8 questionnaire for my research.
Regards
TG Shamase
As a researcher reviewing outcome measures, I find summaries like this extremely efficient. It allows quick evaluation of reliability and construct validity.
I would like to use the MMAS-8 questionnaire for my research.
It’s interesting to learn more about the structure of this instrument and how the different items contribute to the total score.